Trial Profile
A prospective, randomized study of sitagliptin for type-2 diabetes patients with advanced chronic kidney disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2016
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Renal failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 18 Oct 2016 New trial record
- 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes